5+ mon, 3+ week ago   (126+ words) Jay Bregman, founder and CEO of Andel, discusses how employers are managing rising costs for prescription benefits and how pharma companies are shifting their distribution patterns. In the second of his three-part Pharmaceutical Commerce interview, Jay Bregman discusses how rising…...

7+ mon, 1+ week ago   (850+ words) A four-pillar strategy to help ensure both, as copay programs face mounting payer pressure and misuse in 2026. Pharma companies allocate enormous amounts of money to copay programs, one of their largest controllable marketing expenses. These programs began as a way…...

8+ mon, 1+ week ago   (388+ words) In the third part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, explains as medical inflation persists and benefit designs strain under rising drug spend—especially GLP-1s—employers are reaching the limits of what…...

8+ mon, 1+ week ago   (447+ words) In the first part of his Pharma Commerce video interview, Philip Sclafani, PwC’s pharmaceutical and life sciences lead, discusses how from GLP-1 adoption to specialty drugs, behavioral health utilization, and hospital consolidation, multiple forces are reshaping employer-sponsored healthcare costs—and…...

10+ mon, 2+ week ago   (264+ words) First in a three-part series. Next up: what is DTP and who benefits from it? The prize is significant: higher dispense rates, stronger adherence, richer real-world data, and a patient experience that builds - not erodes - brand trust. In a system…...